Our collaborator, Paul D. Slowey from Oasis Diagnostics® Corporation will present the relevance of salivary samples at the #PrecisionEVforum2024 tomorrow in Cambridge. The talk will focus on comparing different saliva EV collection methods and the characterisation of the isolated EVs. The talk will also mark the beginning of ESPDx and Oasis Diagnostics® Corporation collaboration towards the use of saliva EVs as a source of biomarkers for early detection of neurodegenerative disorders. #extracellularvesicles #salivaryEVs #lewybodydementia
ESP Diagnostics Limited
Medical and Diagnostic Laboratories
Newcastle upon Tyne, Tyne & Wear 423 followers
Leading the way in the early diagnosis of Lewy Body Disorders
About us
Neurodegenerative disorders present a huge societal burden, and one from which few of us remain untouched in some way. Unfortunately, by the time a diagnosis is made, it is often too late and irreversible damage is already done. It is essential that patients get examined as early as possible, and that symptoms get diagnosed accurately. This allows the right patients to receive the right treatments at the right time, to help to slow progression, and mitigate symptoms. Pharma and Biotech companies that are developing disease modifying therapies also have a need for biomarkers for neurodegenerative disorders that can help predict disease presence, monitor disease progression and treatment response. ESP Diagnostics is developing scalable liquid-biopsy tests based upon measurements of specific neurodegenerative disease biomarkers in extracellular vesicles (EVs) extracted from blood, saliva and urine. The ESP biomarker tests will allow early pre-symptomatic detection of neurological disorders such as Parkinson’s Disease, Dementia with Lewy Bodies, and a differential diagnosis of Alzheimer’s. We provide assay services to pharma and biotech companies developing disease-modifying therapies (stratification, disease progression, surrogate endpoints, reverse translation, target engagement), and are developing IVD products for patients, clinicians and healthcare providers worldwide.
- Website
-
www.espdiagnostics.com
External link for ESP Diagnostics Limited
- Industry
- Medical and Diagnostic Laboratories
- Company size
- 2-10 employees
- Headquarters
- Newcastle upon Tyne, Tyne & Wear
- Type
- Privately Held
- Founded
- 2022
- Specialties
- diagnostics, patient stratification, neurological disease, Parkinsons, Dementia with Lewy bodies, alpha-synuclein, extracellular vesicles, dementia, and Surrogate endpoints
Locations
-
Primary
Get directions
The Biosphere, Draymans Way, Newcastle Helix
Newcastle upon Tyne, Tyne & Wear NE4 5BX, GB
Employees at ESP Diagnostics Limited
-
Dale Athey
Timely diagnosis of neurodegenerative disorders
-
Marzena Kurzawa-Akanbi
Lecturer in Regenerative Medicine | Academic Founder and CSO of ESP Diagnostics | Inventor
-
Rachel Crossland
Senior Scientist @ESPDx | Researcher in Extracellular Vesicle Biology @NewcastleUniversity | Science Communication Coordinator | Academic Mentor
-
Sonia Guarnerio
Scientist @ ESP Diagnostics. Science illustration and design freelancer.
Updates
-
The statistics present a harsh reality. If we can accelerate early and accurate diagnosis - then we can improve the readiness of healthcare systems to deal with this, and also increase the chances of getting new therapies to market. Detect before the damage is done. #lewybodydementia #neurodegenerative #extracellularvesicles #diagnosis
As the global population ages, dementias, including #AlzheimersDisease, present some of the most urgent health challenges of our time¹,². Lilly welcomes the discussions taking place today on the sidelines of the 2024 G7 Health Ministerial meeting in Ancona, Italy. We look forward to a productive dialogue on the readiness of health care systems for person-centered care and national advancements in improving the Alzheimer’s disease care pathway.
-
-
October is Lewy body dementia (LBD) awareness month. With over 10 million people affected worldwide, awareness of the disease remains low. Initial symptoms can be difficult to recognize and often mistaken for other more common dementias. We join the #lbd community in calling for increased research funding to develop new and advanced diagnostic tools. #lewybodydementia #lewybodydementiaawarenessmonth #dementiadiagnosis
-
-
ESP Diagnostics Limited reposted this
October is Lewy Body Dementia Awareness Month! Let’s unite to spread awareness, support families, and share stories. Every voice matters in raising awareness for LBD. By sharing this post, you are helping us bring awareness to the public!
-
-
ESP Diagnostics Limited reposted this
It was previously believed that 50% of dementia cases were going undiagnosed—a concerning figure on its own. However, recent insights show that 75% of cases are undiagnosed, which is even more alarming. This reinforces the urgent need to raise awareness, reduce stigma, and prioritize early detection. With global dementia cases projected to triple by 2050, immediate action is critical. #dementiaawareness #earlydetection
Did you know that 75% of people living with dementia are doing so undiagnosed? Low levels of awareness, alongside stigma and discrimination can prevent or delay a diagnosis of dementia. Given that global dementia cases are projected to almost triple by 2050, the urgency to act intensifies with every passing year, month, week, day, hour, minute, and second. The time to act is now! This September, join ADI as we campaign for World Alzheimer’s Month, 30 days of global awareness raising, advocacy and action to challenge global stigma surrounding dementia. Every person and every post, re-post, like or comment can make a difference this September! Help us to raise awareness of dementia and address stigma and discrimination and use the hashtags #TimeToActOnDementia #TimeToActOnAlzheimers and #WorldAlzMonth to spread awareness throughout the month. If you have experienced dementia-related stigma after receiving a diagnosis or taking on caring responsibilities then we would love to hear from you and make your story heard. Simply tag us @AlzDisInt
-
-
Exciting news! Our CSO, Marzena Kurzawa-Akanbi, is currently in San Francisco participating in the Ignite North East Accelerator 2024 program. We're on a mission to connect with investors, expand our network and fuel our growth towards the development of our diagnostic tools. If you're in the Bay Area and interested in learning more about our groundbreaking work, reach out to Marzena Kurzawa-Akanbi. Let's connect and discuss how we can collaborate to shape the future of neurodegenerative disorder diagnostics! #startup #innovation #investor #bayarea #accelerator #dementiadiagnosis
The Ignite team is off to San Francisco today with the founders on the North East Accelerator 2024. While there they'll be meeting with key companies, investors and support organisations to discuss growing global businesses from the North East of England.
-
-
ESP Diagnostics Limited reposted this
We are thrilled to announce our BioCap pitching competition finalists! Congratulations to the following: AI Rehab Ltd Alcyomics Brain+ CCI Photonics ClotProtect Therapeutics Ltd EarSwitch ErebaGen ESP Diagnostics Limited Ocuwell Thymotec The winners will be announced at the BioCap conference on 26th September. Read more: https://lnkd.in/effVKe8u PLUS register for BioCap with a conference-only OR combined Delegate Pass & Investor Mixer ticket: Build connections on 25th September ahead of the conference then enjoy an agenda of panel discussions, keynotes and 1-2-1s the next day! https://lnkd.in/eXCvhVs4 #BioCap #Investment #Funding #Networking #LifeSciences #Pitching Sponsors: Bruntwood SciTech | STFC | Mills & Reeve | RSM UK | Appleyard Lees IP LLP | Boyds
-
-
"Alzheimer’s is by far the most commonly diagnosed type of dementia, making up 42.4% of diagnoses in England and about 62% in Scotland. In England, the next most common types of dementia are vascular dementia (15.6%) and mixed dementia, where a patient has more than one type." "However, the diagnosis figures don’t represent the full picture. Hundreds of thousands of people with certain types of dementia, especially Lewy bodies, which includes Parkinson’s disease dementia, may be living without a diagnosis." https://lnkd.in/edzgiTrA
-
Lots of exciting news coming from the #ADLM2024 and #AICC24 meetings in US last month. It's good to see leading Therapeutics and Diagnostics companies Biogen, Beckman Coulter Diagnostics and Fujirebio Diagnostics, Inc. collaborating to drive forward development of Alzheimer's therapies through the use of blood based biomarkers. An example of how blood based biomarker tests can address the growing need to identify, stratify and monitor patients with these complex neurodegenerative disorders. #extracellularvesicles #diagnostics #neurodegenerative #DementiawithLewyBodies
Biogen, Beckman Coulter and Fujirebio partner to develop Alzheimer's Tau blood test
medicaldevice-network.com
-
🔍 A link between α -1 blockers - treatment for urinary symptoms due to enlarged prostate - and a reduced DLB risk was reported in a recent paper issued last week. The increased availability of glycolitic activity might have a protective role in Dementia with Lewy Bodies. 💡 Although further research will be necessary to confirm the link, the study highlights the potential of repositioning drugs already on the market for incurable diseases, such as dementia. Link to the paper for a closer look: https://lnkd.in/etSDR4DV #lewybodydementia #dementiaresearch #drugdiscovery
-